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Abstract
We conducted the first prospective observational study in which we examined the associa-
tion between incretin responses to an oral glucose tolerance test (OGTT) and mixed meal
test (MMT) at baseline and changes in fasting glucose levels 7 years later, in individuals
who were non-diabetic at baseline. We used data from the Hoorn Meal Study; a population-
based cohort study among 121 subjects, aged 61.0±6.7y. GIP and GLP-1 responses were
determined at baseline and expressed as total and incremental area under the curve (tAUC
and iAUC). The association between incretin response at baseline and changes in fasting
glucose levels was assessed using linear regression. The average change in glucose over
7 years was 0.43 ± 0.5 mmol/l. For GIP, no significant associations were observed with
changes in fasting glucose levels. In contrast, participants within the middle and highest
tertile of GLP-1 iAUC responses to OGTT had significantly smaller increases (actually
decreases) in fasting glucose levels; -0.28 (95% confidence interval: -0.54;-0.01) mmol/l
and -0.39 (-0.67;-0.10) mmol/l, respectively, compared to those in the lowest tertile. The
same trend was observed for tAUC GLP-1 following OGTT (highest tertile: -0.32 (0.61;-
0.04) mmol/l as compared to the lowest tertile). No significant associations were observed
for GLP-1 responses following MMT. In conclusion, within our non-diabetic population-
based cohort, a low GLP-1 response to OGTT was associated with a steeper increase in
fasting glucose levels during 7 years of follow-up. This suggests that a reduced GLP-1
response precedes glucose deterioration and may play a role in the etiology of type 2 diabe-
tes mellitus.
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Introduction
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycaemia, which results from a
combination of insulin resistance, increased hepatic glucose production and pancreatic β-cell
dysfunction[1, 2]. Recent evidence indicated that the gastrointestinal system, especially the
incretin hormones, play a significant role in the pathophysiology of T2DM as well[3]. The
growing interest in the use of incretin-based therapies and other interventions in early stages
of the disease underscore the importance to determine the possible etiological role of the incre-
tin hormones in T2DM.
During ingestion of food, the gastrointestinal incretin hormones, glucose-dependent insuli-
notropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are released from the gut
into the bloodstream, where they bind to their specific receptors on the pancreas to regulate
the amount of insulin and glucagon that is secreted to control blood glucose levels. The impor-
tant role of the incretin hormones with regard to insulin secretion becomes apparent when the
same amount of glucose is infused intravenously as opposed to orally ingested; oral glucose
enhances insulin secretion much more than infused glucose: the so-called incretin effect[4, 5].
In healthy people, the incretin effect accounts for at least 50%[6] and up to 70%, of the total
insulin secreted after oral glucose intake and therefore plays an important role in maintaining
normal glucose regulation after meal intake[7, 8]. In T2DM patients, the incretin effect is
severely reduced[9] and the impairment is thought to explain an important part of the im-
paired insulin secretion seen in T2DM[10].
Besides stimulating insulin secretion, through several pathways [11], the incretins have
additional effects, both on postprandial metabolism, as well as on pathways that may exert
long-term metabolic effects. In the postprandial state, GIP stimulates and GLP-1 suppresses
glucagon secretion. In addition, GLP-1 lowers hepatic glucose production, increases glucose
uptake in the muscles and slows gastric emptying[6, 12]. Long-term effects of the incretins
include central nervous system effects to regulate appetite and food intake and also involve
cardiovascular and neurotropic effects[6, 12]. Given the wide range of glucoregulatory actions
of the incretin hormones and their importance in maintaining glucose homeostasis it was
hypothesized that incretin responses are associated with changes in fasting glucose over time.
Up until now, only cross-sectional studies have investigated alterations in incretin
responses, which have shown inconclusive results with GLP-1 and GIP being increased[10, 13,
14], decreased [15–22] or normal[16, 23–26] in T2DM and pre-diabetes. Meta-analyses of
Calanna et al. 2013[27, 28] in T2DM patients, showed an overall preserved GIP[27] and unal-
tered GLP-1[28] secretion. However, there was substantial heterogeneity between studies, in
particular for GLP-1 responses and stratified analyses showed different results for liquid versus
solid meals. In a report on the cross-sectional data of our population-based cohort, GIP and
GLP-1 responses (tAUC) were increased in T2DM patients, but not in persons with intermedi-
ate hyperglycaemia[29].
However, these cross-sectional findings should be interpreted carefully, because compari-
son between diseased and healthy individuals may be confounded by other metabolic alter-
ations, such as differences in body mass index (BMI) and rate of gastric emptying in T2DM
[30]. Prospective studies among non-diseased individuals could provide more insight into the
role of incretins in the etiology of T2DM[31], by studying the relationship between incretin
hormone response and glucose deterioration over time. Therefore, we conducted the first
prospective observational study in which we examine the association between incretin
responses to an oral glucose tolerance test (OGTT) and mixed meal test (MMT) at baseline
and changes in fasting plasma glucose levels 7 years later, in individuals who were non-diabetic
at baseline.
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Materials and methods
Study population
The study participants were from the Hoorn Meal Study, which involves a population-based
cohort of 40–65 year old men and women, all Caucasian, initiated in the year 2005[29, 32].
The study population consisted of 208 participants of which 194 persons were randomly
invited from the general population in Hoorn, the Netherlands and 14 patients with T2DM
were recruited from the regional Diabetes Care System. Details of the inclusion procedure
were described earlier[29, 32]. After 7 years, a follow-up examination was carried out. Of the
remaining 187 participants who were invited for the follow-up examination, 129 (69%) agreed
to participate. For the current study, participants with T2DM at baseline (n = 5) or participants
without glucose measures at follow-up (n = 3) were excluded, resulting in a study population
of 121 subjects. All participants signed informed consent and the medical ethics committee of
the VU University Medical Centre approved the study.
Study procedure
At the baseline examination, participants received a 75g-OGTT and a standardized MMT after
an overnight fast, on separate days, in random order, within 2 weeks. Except for the OGTT or
test meal and a small amount of water, participants refrained from food, drinks and physical
activity during the test. During the OGTT, blood samples were drawn in the fasting state and
at 15, 30, 60, 90 and 120 minutes following glucose intake. The MMT was a standardized
mixed breakfast consisting of 2 croissants (90g), 10g butter, 40g cheese, 150g full-fat milk and
100g of yoghurt drink enriched with 10g of maltose. The total nutrient content was 3487kJ
(74g (36 Energy%) carbohydrates, 49g (52 Energy%) fat of which 28g was saturated and 24g
(12 Energy%) proteins). Blood samples were collected in fasting state and at 15, 30, 60, 90, 120,
180 and 240 minutes following meal intake. Blood samples were drawn from the antecubital
vein, immediately processed after sampling and stored at -80C˚.
After 7 years of follow-up, a physical examination was performed, including measurement
of fasting plasma glucose levels, lifestyle factors and anthropometry. For the measurement of
fasting plasma glucose levels a blood sample was taken after an overnight fast.
GIP and GLP-1 levels
The blood samples drawn during the OGTT and MMT were assessed for GIP and GLP-1 lev-
els. Total GLP-1 levels were determined using RIA (antiserum 89390) against standards of syn-
thetic GLP-1 7–36 amide. The assay measures the sum of intact GLP-1 and the primary
metabolite, GLP-1 9–36 amide[33]. Total GIP levels were measured using the COOH termi-
nally directed antiserum R65, which fully reacts with intact human GIP and the NH2 termi-
nally truncated metabolite[34]. For both assays, sensitivity was below 1pmol/l and intra-assay
coefficients of variation below 6% at 20 pmol/l. In order to minimize inter-assay variation, all
samples were run consecutively and without delay, using identical reagents and protocols.
Outcome
Primary outcome was defined as the change in fasting plasma glucose levels (continuous out-
come) during a median 7.0±0.2 year follow-up. Fasting plasma glucose levels at baseline and
follow-up were determined using the glucose hexokinase method Modular analytics, Roche
diagnostics, Mannheim, Germany, with intra- and inter-assay coefficients of variation of 1.5%
and 1.5%, respectively.
Incretin response and change in glucose level over time
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Other measures
Age and sex were self-reported. We measured weight and height, with participants wearing
light clothes only, and the BMI was calculated as weight/height squared (kg/m2). Waist cir-
cumference was measured according to a standardised procedure, as described earlier[35].
Sitting blood pressure was measured twice on the right arm with a random-zero sphygmoma-
nometer (Hawksley–Gelman, Lancing, UK) and the average was used. Level of insulin was
measured from a fasted blood sample by immunometric assays (ACS Centaur, Bayer Diagnos-
tics, Mijdrecht, The Netherlands). The insulinogenic index was calculated by dividing the
increment in insulin during the first 30 min of OGTT/MMT by the increment in glucose over
the same period [36]. HOMA-IR was calculated using the following equation: HOMA-IR =
(fasting plasma insulin × fasting plasma glucose) / 22.5 [37].
Statistical analyses
Characteristics of study participants. First, possible selection bias was investigated by
comparing age, sex, BMI, fasting plasma glucose and 2h plasma glucose levels at baseline
between participants who participated (n = 126) in the follow-up examination and those who
did not (n = 82), using Student’s t-test for continuous variables and Chi-Square tests for
dichotomous variables.
Baseline characteristics of the final study population (n = 121) were presented. Continuous
data were presented as mean ± standard deviation (SD) or median (interquartile range (IQR))
when variables were skewed, while dichotomous data were presented as %.
Analysis of GIP and GLP-1 levels. GIP and GLP-1 responses following OGTT and MMT
were measured as the total area under the curve (tAUC) as well as the incremental area under
the curve (iAUC), the latter only measuring the area above baseline level. The AUC was calcu-
lated using the trapezoid method for the total duration of the OGTT and MMT, 2 hours and 4
hours, respectively. Linearity was checked for continuous determinants. Due to the non-linear
associations that were observed, AUC data were grouped into tertiles.
Associations with fasting plasma glucose levels at baseline. To examine the cross-sec-
tional association between the tAUC and iAUC of the incretin hormones and fasting glucose
levels at baseline, unstandardized regression coefficients were estimated, using linear regres-
sion analyses. Although age, sex and BMI were not associated with incretin responses at the
baseline measurement[29], we adjusted for these variables in our analysis because BMI, age
and sex are known as important determinants of glucose levels and diabetes[16, 20]. We also
assessed whether sex was a possible effect modifier.
Associations with fasting plasma glucose levels after 7 years of follow-up. To examine
the prospective association between the tAUC and iAUC of the incretin hormones and
changes in fasting glucose levels during 7 years of follow-up, unstandardized regression coeffi-
cients were estimated, using linear regression analyses. While fasting glucose levels at follow-
up were expected to be higher in participants with already higher fasting glucose levels at base-
line, the so called ‘horse-racing effect’, we adjusted for fasting glucose levels at baseline in all
models and subsequently for age, sex, follow-up duration and BMI (model 2). In additional
analyses, we adjusted for possible mediating factors; insulinogenic index as a marker of beta-
cell function and HOMA-IR as a marker of insulin sensitivity (model 3). Due to the limited
number of participants, we restricted the number of confounders or mediators.
To assess possible selection bias due to drop-outs at follow-up, we performed a sensitivity
analysis using inverse probability weighting (IPW) analysis, based on propensity scores, to
adjust for baseline differences between participants who participated in the follow-up exami-
nation and those who did not. With IPW, a logistic regression analysis is performed to
Incretin response and change in glucose level over time
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estimate the probability of participating at follow-up for a particular individual and then the
inverse of the predicted probability is used as a weight in the subsequent linear regression anal-
ysis. Individuals who are less likely to be present at follow-up, based on their baseline charac-
teristics, are weighted most heavily in the subsequent linear regression analysis.
Finally, we also examined the prospective association of the fasting, 30 minute and 2h incre-
tin levels separately with changes in fasting glucose levels during 7 years of follow-up. For
these additional analyses, the same models were used as for the main analyses.
Associations with BMI and waist after 7 years of follow-up. Along with its insulinotro-
pic effects, GIP enhances fat deposition and GLP-1 reduces food intake and body weight,
thereby potentially exacerbating and improving obesity, respectively[38, 39]. Therefore, we
also examined the prospective association of incretin levels with changes in BMI and waist cir-
cumference during 7 years of follow-up. The analyses were adjusted for BMI or waist circum-
ference at baseline and subsequently for age, sex and follow-up duration.
Statistical analyses were performed with SPSS version 20.0 (SPSS Inc., Chicago, IL) and a p-
value below 0.05 was considered to be statistically significant.
Results
Characteristics of study participants
Compared to the 121 participants who took part in the follow-up examination after a median
7.0±0.2 year follow-up, those who declined participation had a significantly higher BMI (28.6
vs. 26.9 kg/m2, p = 0.01), waist circumference (99 vs. 94 cm, p = 0.006), fasting glucose levels
(6.0 vs. 5.5 mmol/l, p = 0.001) and 2h plasma glucose levels (6.6 vs. 5.2 mmol/l, p = 0.001) at
baseline. No significant age and sex differences were observed.
The baseline characteristics of the study population (n = 121), including levels of fasting,
tAUC and iAUC concentrations of GLP-1 and GIP, are described in Table 1. Of the 121 partic-
ipants without T2DM at baseline, 9 participants (7.4%) had developed T2DM after 7 years of
follow-up.
Associations with fasting glucose levels at baseline
Results of the linear regression analyses between the tAUC and iAUC of GIP and GLP-1 and
fasting glucose levels at baseline are shown in S1 and S2 Tables. Sex was not an effect modifier.
No significant associations were observed for GIP levels. For tAUC GLP-1 following MMT,
but not following OGTT, we observed that in the crude model, those with GLP-1 responses in
the middle and highest tertile had significantly lower fasting glucose levels compared to those
in lowest tertile (-0.28 (95% CI: -0.47; -0.08) mmol/l and -0.27 (95% CI: -0.46; -0.08) mmol/l,
respectively). Similar results were observed after additional adjustment for age, sex and BMI.
For iAUC GLP-1, a significant association was observed, in the crude model, for the highest as
compared to the lowest tertile following OGTT, but not MMT (-0.23 (95% CI: -0.42;–0.04)
mmol/l). However this association was no longer significant after adjustment for additional
confounders.
Associations with changes in fasting glucose levels during 7 years of follow-
up
The mean change in fasting glucose levels during 7 years of follow-up was 0.43 ± 0.5 mmol/l
(p = 0.000), resulting in a mean fasting glucose level at follow-up of 5.83 ± 0.7 mmol/l. Results
of the linear regression analyses between the tAUC and iAUC of GIP and GLP-1 at baseline
and changes fasting glucose levels after 7 years of follow-up are shown in Tables 2 and 3. Sex
Incretin response and change in glucose level over time
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was not an effect modifier. No significant associations were observed for GIP levels. However,
individuals in the lowest tertile of iAUC GLP-1 following OGTT had an increase of 0.95
mmol/l in fasting glucose levels during 7 years of follow-up. Those in the middle and highest
tertiles had a significantly smaller increase (in fact, decreases) in fasting glucose levels during
follow-up, adjusted for fasting glucose levels at baseline, compared to those in lowest tertile;
-0.28 (95% CI: -0.54;–0.03) mmol/l and -0.38 (95% CI: -0.65;–0.12) mmol/l, respectively
(Table 3). Similar results were observed after adjustment for additional confounders; age, sex,
follow-up duration and BMI. Further adjustment for possible mediating variables; insulino-
genic index and HOMA-IR also did not affect the associations. For the tAUC GLP-1, the same
trend was observed; following OGTT, those in the highest tertile had a significantly smaller
increase in fasting glucose levels (Table 2). No significant associations were observed for GLP-
1 levels following the MMT.
In the sensitivity analyses using IPW, the association of the tAUC and iAUC of GLP-1 fol-
lowing OGTT with the change in fasting glucose levels during follow-up became more pro-
nounced. For the iAUC of GLP-1, the regression coefficients, in the baseline glucose, age, sex,
follow-up duration and BMI adjusted model, for those in the middle and highest tertiles, com-
pared to those in lowest tertile, were; -0.30 (95% CI: -0.57; -0.03) and -0.42 (95% CI:-0.71;
-0.12), respectively. For the tAUC of GLP-1, the regression coefficients were; -0.16 (95% CI:
-0.42; 0.11) and -0.36 (95% CI: -0.65; -0.06), respectively. Furthermore, excluding individuals
who were on lipid lowering or antihypertensive medication, did not change the estimates. For
the iAUC of GLP-1, the regression coefficients, adjusted for baseline glucose, age, sex, follow-
up duration and BMI, for those in the middle and highest tertiles, compared to the lowest
Table 1. Population characteristics at baseline (n = 121).
Sex (% female) 50.4
Age (years) 54.1 ± 6.6
Body mass index (kg/m2) 26.7 ± 3.7
Waist circumference (cm) 93.1 ± 11.2
Systolic blood pressure (mm/Hg) 134.7 ± 15.8
Diastolic blood pressure (mm/Hg) 76.8 ± 9.3
Fasting glucose (mmol/l) 5.4 ± 0.4
2h glucose OGTT (mmol/l) 5.0 ± 1.3
Fasting GIP (pmol/l) 6.3 (6.3)
Fasting GLP-1 (pmol/l) 11.0 (4.8)
Fasting insulin (pmol/l) 40.9 (30.4)
tAUC GIP OGTT (mmol/lmin) 82.3 (59.9)
tAUC GLP-1 OGTT (mmol/lmin) 34.9 (19.5)
tAUC GIP MMT (mmol/lmin) 299.2 (184.1)
tAUC GLP-1 MMT (mmol/lmin) 64.4 (29.5)
iAUC GIP OGTT (mmol/lmin) 72.3 (56.3)
iAUC GLP-1 OGTT (mmol/lmin) 12.0 (12.5)
iAUC GIP MMT (mmol/lmin) 275.8 (176.6)
iAUC GLP-1 MMT (mmol/lmin) 23.9 (26.9)
Hypertension medication (n, %) 8, 7
Lipid lowering medication (n, %) 19,16
Values are mean ± SD, or median (interquartile range) in case of a skewed distribution.
Duration of OGTT is 2h, duration MMT is 4h. tAUC = total area under the curve, iAUC = incremental area under
the curve.
https://doi.org/10.1371/journal.pone.0191114.t001
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tertile, were; -0.29 (95% CI: -0.60; -0.02) and -0.40 (95% CI: -0.74; -0.06), respectively. For the
tAUC of GLP-1, the regression coefficients were; -0.18 (95% CI: -0.47; 0.12) and -0.34 (95%
CI: -0.69; 0.01), respectively.
When the association between incretin response and changes in fasting glucose levels was
examined, using only the fasting, 30 minute or 2h OGTT levels instead of the AUC, no signifi-
cant associations were observed. These results suggested that incretin levels at single time
points were not predictive and cannot be used instead of the AUC of the incretin response.
The regression coefficients for the middle and highest tertile of fasting GLP-1, compared to
the lowest tertile, adjusted for fasting glucose levels at baseline, were; 0.03 (95% CI: -0.20; 0.27)
and -0.13 (95% CI:-0.36; 0.11), respectively. For the fasting levels of GIP, the regression coeffi-
cients were; 0.09 (95% CI: -0.14; 0.32) and -0.05 (95% CI: -0.30; 0.19), respectively. The regres-
sion coefficients for the middle and high tertile of 30 minute OGTT levels of GLP-1, compared
to the lowest tertile, adjusted for fasting glucose levels at baseline, were; -0.10 (95% CI: -0.35;
0.15) and -0.20 (95% CI: -0.44; 0.04), respectively. For the 30 minute OGTT levels of GIP, the
regression coefficients were; 0.02 (95% CI: -0.22; 0.27) and -0.02 (95% CI: -0.28; 0.22), respec-
tively. Finally, the regression coefficients for the middle and highest tertile of 2h OGTT levels
of GLP-1, compared to the lowest tertile, adjusted for fasting glucose levels at baseline, were;
0.16 (95% CI: -0.09; 0.41) and -0.10 (95% CI: -0.35; 0.14), respectively. For the 2h OGTT levels
of GIP, the regression coefficients were; -0.05 (95% CI: -0.29; 0.20) and 0.09 (95% CI: -0.15;
0.34), respectively.
Table 2. Regression coefficients (with 95% confidence intervals) for the association of the tAUC of GIP and GLP-
1 following OGTT and MMT at baseline and change in fasting plasma glucose levels during 7.0 years of follow-up.
Model 1 Model 2 Model 3
GIP tAUC OGTT N = 107 N = 107 N = 105
Low (reference) 0.51 (-0.92; 1.95) 0.48 (-3.47; 4.43) 0.93 (-3.40; 5.26)
Middle -0.02 (-0.29; 0.25) -0.06 (-0.33; 0.21) -0.05 (-0.32; 0.22)
High -0.09 (-0.35; 0.18) -0.07 (-0.34; 0.21) -0.02 (-0.29; 0.25)
GIP tAUC MMT N = 106 N = 106 N = 99
Low (reference) 0.67 (-0.70; 2.03) 0.61 (-2.94; 4.16) 0.70 (-3.07; 4.48)
Middle 0.14 (-0.12; 0.40) 0.14 (-0.12; 0.40) 0.15 (-0.12; 0.42)
High -0.03 (-0.29; 0.23) 0.01 (-.26; 0.28) 0.04 (-0.25; 0.32)
GLP-1 tAUC OGTT N = 105 N = 105 N = 103
Low (reference) 0.64 (-0.80; 2.08) 0.53 (-3.43; 4.49) 1.12 (-3.16; 5.40)
Middle -0.15 (-0.41; 0.11) -0.15 (-0.41; 0.12) -0.12 (-0.37; 0.14)
High -0.33 (-0.59; -0.06) -0.32 (-0.61; -0.04) -0.31 (-0.60; -0.03)
GLP-1 tAUC MMT N = 107 N = 107 N = 100
Low (reference) 1.24 (-0.21; 2.68) 0.89 (-2.56; 4.34) 1.03 (-2.64; 4.71)
Middle -0.19 (-0.46; 0.07) -0.22 (-0.49; 0.05) -0.19 (-0.47; 0.09)
High -0.21 (-0.48; 0.05) -0.22 (-0.48; 0.04) -0.22 (-0.49; 0.05)
Note that only for the ‘middle’ and ‘high’ categories regression coefficients are presented. For the ‘low’ category
intercepts are presented. Note that individual parameters have missing data.
Models
1: Adjusted for fasting glucose levels at baseline.
2: Adjusted for fasting glucose levels at baseline, age, sex, follow-up duration and BMI.
3: Adjusted for fasting glucose levels at baseline, age, sex, follow-up duration, BMI, insulinogenic index and
HOMA-IR.
Bold = significant association.
https://doi.org/10.1371/journal.pone.0191114.t002
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Associations with BMI and waist during 7 years of follow-up
Results of the linear regression analyses between the tAUC and iAUC of GIP and GLP-1 at
baseline and changes in BMI and waist circumference after 7 years of follow-up are shown in
S3 and S4 Tables. In general, only small differences were observed between the groups. For
GIP, no significant associations were observed with changes in BMI and waist circumference.
For GLP-1, compared to those in the lowest tertile of the tAUC following MMT, participants
in the highest tertile had a statistically significant smaller increase in BMI; -1.03 kg/m2 (95%
confidence interval: -1.89;-0.16) mmol/l (S3 Table). The same was observed for the iAUC of
GLP-1 following OGTT; those in the highest tertile had a statistically significant smaller
increase in BMI; -1.00 kg/m2 (95% confidence interval: -1.91;-0.09). Although participants in
the highest GLP-1 tertile also seemed to have a smaller increase in waist circumference, except
for iAUC GLP-1 following MMT (S4 Table), no significant associations were observed
between GLP-1 and changes in waist circumference.
Discussion
To our knowledge, this study is the first prospective study to examine the association of incre-
tin responses to an OGTT and MTT at baseline and the change in fasting plasma glucose dur-
ing 7 years of follow-up, in individuals who were non-diabetic at baseline. Up until now, the
cross-sectional evidence on the aetiological role of the incretin hormones in T2DM has been
Table 3. Regression coefficients (with 95% confidence intervals) for the association of the iAUC of GIP and GLP-
1 following OGTT and MMT at baseline and change in fasting plasma glucose levels during 7.0 years of follow-up.
Model 1 Model 2 Model 3
GIP iAUC OGTT N = 107 N = 107 N = 105
Low (reference) 0.54 (-0.91; 1.20) 0.61 (-3.34; 4.56) 1.06 (-3.35; 5.37)
Middle -0.03 (-0.29; 0.24) -0.09 (-0.37; 0.18) -0.08 (-0.36; 0.19)
High -0.05 (-0.32; 0.21) -0.05 (-0.32; 0.22) -0.003 (-0.27; 0.26)
GIP iAUC MMT N = 106 N = 106 N = 99
Low (reference) 0.80 (-0.58; 2.19) 0.64 (-2.95; 4.22) 0.82 (-2.99; 4.64)
Middle -0.07 (-0.34; 0.19) -0.06 (-0.33; 0.21) -0.01 (-0.29; 0.27)
High -0.08 (-0.34; 0.18) -0.02 (-0.29; 0.26) -0.04 (-0.32; 0.25)
GLP-1 iAUC OGTT N = 105 N = 105 N = 103
Low (reference) 1.07 (-0.41; 2.56) 0.95 (-3.00; 4.91) 1.06 (-3.23; 5.34)
Middle -0.28 (-0.54; -0.03) -0.28 (-0.54; -0.01) -0.27 (-0.53; 0.001)
High -0.38 (-0.65; -0.12) -0.39 (-0.68; -0.10) -0.35 (-0.63; -0.06)
GLP-1 iAUC MMT N = 107 N = 107 N = 100
Low (reference) 0.92 (-0.48; 2.32) 1.11 (-2.37; 4.58) 1.14 (-2.56; 4.84)
Middle 0.11 (-0.15; 0.37) 0.14 (-0.14; 0.41) 0.07 (-0.21; 0.35)
High -0.01 (-0.27; 0.24) 0.05 (-0.22; 0.32) 0.03 (-0.26; 0.32)
Note that only for the ‘middle’ and ‘high’ categories regression coefficients are presented. For the ‘low’ category
intercepts are presented. Note that individual parameters have missing data.
Models
1: Adjusted for fasting glucose levels at baseline.
2: Adjusted for fasting glucose levels at baseline, age, sex, follow-up duration and BMI.
3: Adjusted for fasting glucose levels at baseline, age, sex, follow-up duration, BMI, insulinogenic index and
HOMA-IR.
Bold = significant association.
https://doi.org/10.1371/journal.pone.0191114.t003
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inconclusive[10, 13–26, 29, 40]. In our current prospective analyses (without T2DM patients)
GIP response was not associated with fasting glucose levels at baseline or with a change in fast-
ing glucose levels during follow-up. In contrast, for GLP-1 both the cross-sectional baseline as
the prospective analyses showed an inverse association between GLP-1 and (change in) fasting
glucose, suggesting that a low GLP-1 response was predictive for glucose deterioration.
Comparison of our results to previous studies is hampered by the cross-sectional design of
those studies[10, 13–26, 29]. Up until now, the predominant view was that altered incretin secre-
tion is unlikely to be an initial defect in the aetiology of T2DM and instead is a consequence of
the diabetic state[17, 40–42]. For example, in a study of identical twins, discordant for diabetes,
only the one with T2DM showed impaired GLP-1 secretion, suggesting that an impairment in
GLP-1 secretion may be a consequence of T2DM[17]. However, a recent study of Færch et al.
(2015) challenged this view, showing that the GLP-1 response to an OGTT was impaired in sub-
jects with pre-diabetes, suggesting that changes in GLP-1 secretion precede glucose deterioration
rather than being a consequence of it[20]. Although results of previous cross-sectional studies
should be interpreted carefully, the results from Færch et al. (2015) are in line with ours, which
indicate that reduced GLP-1 secretion does indeed predict glucose deterioration. While our
study is the first prospective study, additional studies are necessary to replicate these results.
Our current observation that only the secretion of GLP-1 and not GIP was significantly
associated with a change in fasting glucose levels during follow-up can be seen as unexpected,
as the two incretin hormones are very similar with respect to insulinotropic effects, i.e. recep-
tors and signal transduction mechanisms[43, 44]. However, GLP-1 and GIP have dissimilar
metabolic effects, with GLP-1 being more favorable for glucose homeostasis and energy bal-
ance, as GLP-1 directly inhibits glucagon and increases satiety and thereby reduces energy
intake[6, 38]. In contrast, GIP is involved in energy storage and fat deposition, which when
chronic, promotes diabetes development[45]. In our analyses, an association was observed for
GLP-1 but not for GIP with changes in BMI over time, with high levels of GLP-1 being associ-
ated with a smaller increase in BMI, compared to those with low levels of GLP-1. This is in line
with previous studies showing that GLP-1 reduces food intake and body weight [38, 39].
While our study is the first prospective study, we need additional studies to confirm these
results and provide possible (metabolic) explanations for the observation that only the secre-
tion of GLP-1 and not GIP was associated with changes in fasting glucose levels.
The second unexpected result was the absence of a significant association between GLP-1
response and glucose concentrations at follow-up after a MMT, which was significant for the
response after an OGTT. This discrepancy might be explained by the overall lower and slower
incretin response to the MMT as compared to the OGTT, making it harder to distinguish dif-
ferences. Finally, we observed differences in association for the tAUC versus the iAUC. For
tAUC, the association following the MMT was similar to that of the OGTT, albeit not signifi-
cant, while this was not the case for iAUC. This difference could be explained by the fact that
the tAUC is predominantly dependent on the fasting levels, which are expected to be very sim-
ilar between the MMT and OGTT[27]. As the iAUC is more dependent on the load and the
response is thus more dissimilar between the MMT and OGTT, this possibly explains our
observed difference. However, as our study is the first prospective study, additional studies are
necessary to support these results.
Our study has some limitations. First, the number of subjects investigated in this study is
rather limited and studies with larger sample sizes are required to confirm our results. How-
ever, we feel that the need for a population-based, prospective study, on this topic outweighs
the limited number of subjects. Second, because only 9 participants developed T2DM at fol-
low-up, we were unable to assess the association between the incretins and incident T2DM,
due to lack of statistical power. Third, while we have not conducted OGTT’s or determined
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insulin and glucagon levels at follow-up and HbA1c data is lacking at baseline, our analyses are
limited to (change in) fasting glucose levels at follow-up, not reflecting total glucose metabo-
lism or insulin sensitivity status. Fourth, our results might also be explained by an age depen-
dent decline of GLP-1 response. However, our analyses were corrected for age at baseline and
in addition, Færch et al. (2015) showed a positive association between age and GLP-1 response,
not a negative one[20]. Fifth, as with any observational prospective study, the baseline mea-
surement of the exposure, the incretin response, may not reflect the exposure during the
(entire) follow-up period, and may have changed upon factors such as diet or medication.
Unfortunately no information on changes of diet or drug exposure during follow-up was avail-
able. Finally, the participants included in the analysis were significantly healthier compared to
the participants who declined participation at follow-up and this could have led to an underes-
timation of observed associations. Indeed, in a sensitivity analysis using IPW to adjust for
selection by such drop-outs, the association of the tAUC and iAUC of GLP-1 following OGTT
with the change in fasting glucose levels during follow-up became more pronounced.
The main strength of this study is that we were able to conduct a prospective study on the
association of the incretin hormones with change in fasting glucose levels. Second, extensive
baseline measures were conducted, including an OGTT as well as a MMT, which provides
additional information on the normal physiological response after eating a meal. Third, ana-
lyzing a generally healthy population at baseline reduces the role of major potential confound-
ers such as variations in the rate of gastric emptying. In addition, adjusting for possible
confounders or mediating variables, including indicators of insulin sensitivity or beta-cell
function, or overweight, did not explain the observed associations. Neither did exclusion of
individuals who were using antihypertensive or lipid lowering drugs at baseline. Fourth, incre-
tin analyses were made at the time of plasma sampling. Any other study design would have
caused problems because of long term storage of plasma samples (retrospective studies) or
because of a 3 times greater inter-assay variation than intra-assay variation (prospective stud-
ies). Finally, we measured plasma total GIP and GLP-1 levels and not plasma intact GIP and
GLP-1 levels. Plasma concentrations of total GIP and GLP-1 include the intact, active hor-
mone and the inactive primary metabolites of GIP and GLP-1 and are therefore better indica-
tors of the overall secretory response than plasma intact incretin levels as these are rapidly
degraded by the enzyme DPP4 [12].
In conclusion, the current study suggests a low GLP-1 response to an OGTT to be associ-
ated with a steeper increase in fasting plasma glucose levels over time. These results support
the hypothesis that reduced GLP-1 secretion precedes glucose deterioration and this reduction
might play a role in the etiology of T2DM.
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